Axel Bolte
Founder presso INOZYME PHARMA, INC.
Patrimonio netto: 2 M $ in data 29/02/2024
Profilo
Axel Bolte founded Inozyme Pharma, Inc. He is on the board of Nabriva Therapeutics GmbH, Tripex Pharmaceuticals LLC and Inozyme Pharma, Inc. (former President, Chief Executive Officer & Director).
In the past he held the position of Managing Member at Healthcare Advisors GmbH, Investment Manager at Nmt New Medical Technologies AG, Venture Partner at HBM Partners AG and Investment Manager at New Medical Technologies AG (a subsidiary of HBM Partners AG) and Scientist at Serono SA.
Axel Bolte received an MBA from the University of St. Gallen, a graduate degree from Swiss Federal Institute of Technology and an undergraduate degree from the University of Cambridge.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
INOZYME PHARMA, INC.
0.43% | 13/06/2023 | 266 696 ( 0.43% ) | 2 M $ | 29/02/2024 |
Posizioni attive di Axel Bolte
Società | Posizione | Inizio |
---|---|---|
INOZYME PHARMA, INC. | Founder | 01/09/2015 |
Tripex Pharmaceuticals LLC
Tripex Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Tripex Pharmaceuticals LLC provides pharmaceutical services. The company is headquartered in Encinas, CA. | Director/Board Member | - |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Director/Board Member | 01/01/2007 |
Precedenti posizioni note di Axel Bolte
Società | Posizione | Fine |
---|---|---|
IVERIC BIO, INC. | Director/Board Member | 11/07/2023 |
Healthcare Advisors GmbH | Corporate Officer/Principal | 01/09/2019 |
ALLENA PHARMACEUTICALS, INC. | Director/Board Member | 05/06/2019 |
NABRIVA THERAPEUTICS PLC | Director/Board Member | 01/08/2018 |
PTC THERAPEUTICS, INC. | Director/Board Member | 01/07/2014 |
Formazione di Axel Bolte
University of Cambridge | Undergraduate Degree |
University of St. Gallen | Masters Business Admin |
Swiss Federal Institute of Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 6 |
---|---|
PTC THERAPEUTICS, INC. | Health Technology |
NEWRON PHARMACEUTICALS S.P.A. | Health Technology |
ENANTA PHARMACEUTICALS, INC. | Health Technology |
INOZYME PHARMA, INC. | Health Technology |
NABRIVA THERAPEUTICS PLC | Health Technology |
ALLENA PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 14 |
---|---|
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Health Technology |
ZP Opco, Inc.
ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
New Medical Technologies AG | Finance |
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Health Technology |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
IVERIC bio, Inc.
IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Tripex Pharmaceuticals LLC
Tripex Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Tripex Pharmaceuticals LLC provides pharmaceutical services. The company is headquartered in Encinas, CA. | Health Technology |
Healthcare Advisors GmbH | |
Nmt New Medical Technologies AG |